Community News
Get the latest news from NTSAD about our Community, the research that provides hope, and what is happening in the world of rare disease.
Latest Issue – July 2023
In this issue:
- Azafaros GM2 Clinical Trial
- New Directory of Patient Samples
- Working for Noa: Canavan GeneOften referred to as the "unit of heredity." A gene is composed of a sequence of DNA required to produce a functional protein. More Therapy
- Join Us in a Day of Hope
- The Manning Family: 20 Years of Honoring Dylan
- Stephanie Wright: Living with Late Onset Disease
- Why I Give to The Buryk Research Fund
- Imagine & Believe 2023
- Gottlieb Scholarship for Rare Siblings
Subscribe
FEATURED ARTICLE
Azafaros Recruiting for GM2 Clinical Trial
Azafaros, a biotech company based in the Netherlands, began recruiting for its RAINBOW Study, a phase 2 multinational trial for Tay-Sachs, Sandhoff, (known collectively as GM2) and Niemann-Pick Type C. The study will be held in Brazil and the United States.
Recently, NTSAD and the National Niemann-Pick Disease Foundation hosted a community meeting with Azafaros about the RAINBOW study and answered questions from rare families. The Phase 2 RAINBOW study is a randomized, double-blind, placebo-controlled, multicenter, 12-week trial assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZ-3102 in patients with GM2 gangliosidosis and NP-C. The study will enroll 12 patients in total (six with GM2 and six with NP-C), aged 12 to 20 years, each of whom will receive either the low dose, high dose, or a placebo. Patients who complete the 12-week study period will be offered a double-blind extension if approved by the country’s health authorities. The aim of the short study is to determine the clearance of AZ-3102 from the body and the effect of two different doses in patients to identify the target dose for Azafaros’ planned Phase 3 pivotal studies.
Watch the community meeting with Azafaros about the RAINBOW Study, now available on NTSAD’s YouTube channel.
Previous Issues
Click the issue you wish to read from the list below:
